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Abstract
Background: Schistosomiasis japonica is a zoonotic parasitic disease and oral vaccine delivery system would be benefit for
prevention of this disease. Although attenuated salmonella has been used as an antigen expression vector for oral vaccine
development, the membrane-bound vacuoles in which bacteria reside hinders the presentation of expressed heterologous
antigens to the major histocompatibility complex (MHC) molecules. The present work used an attenuated Salmonella
typhimurium strain VNP20009 to secretory expression of Sj23LHDGST bivalent antigen from Schistosoma japonicum and
tested the protective efficacy against S. japonicum infection in orally immunized mice.
Methodology/Principal Findings: Promoters (nirB or pagC) were used to express the antigen (Sj23LHDGST) and the
Salmonella type III or a-hemolysin secretion system was employed to secrete it. The immunoblotting analysis and
fluorescent microscopy revealed that the antigen was effectively expressed and delivered to the cytosol of macrophages in
vitro. Among recombinant vaccine strains, an engineered VNP20009 which expressed the antigen by nirB promoter and
secreted it through type III secretion system (nirB-sopE1–104-Sj23LHD-GST) efficiently protected against S. japonicum
infection in a mouse model. This strain elicited a predominantly IgG2a antibody response and a markedly increase in the
production of IL-12 and IFN-c. The flow cytometric analysis demonstrated that this strain caused T cell activation as
evidenced by significantly increased expression of CD44 and CD69.
Conclusion/Significance: Oral delivery of antigen by nirB-driven Salmonella typhimurium type III secretion system is a novel,
safe, inexpensive, efficient and convenient approach for schistosome vaccine development.
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Introduction
Schistosomiasis, a disease cause by intravascular trematodes
from the schistosome species, is one of the world’s major public
health problems [1]. It is estimated that 200 million people in
seventy countries or regions from Africa, Asia and South America
are infected with schistosomes [2]. Five schistosome species infect
humans including Schistosoma (S.) japonicum, S. mansoni, S. mekongi, S.
intercalatum, and S. haematobium. Despite that numerous strategies
have been devised and chemotherapeutic drugs such as prazi-
quantel have been developed to combat this infectious disease,
schistosomiasis still defies effective control [3]. It is generally
agreed that chemotherapy has certain limitations and drug-
resistance hampers its effectiveness [4]. Furthermore, praziquantel,
the treatment of the first choice for schistosomiasis, is not useful as
a preventive agent because its actions last only a few hours [3],
besides, it is not effective against schistosomulum.
Several Schistosome vaccines have been developed, including
DNA vaccines [5], peptide vaccines [6], recombinant protein
vaccines [7] and multivalent vaccines[8]. These vaccines targeted
antigens such as glutathione S-transferase (GST), triose-phosphate
isomerase (SjTPI), paramyosin (Sj97), fatty acid binding protein
(FABP, Sj14), and 23 kDa membrane protein (Sj23). These
vaccines were tested in animal models and so far have been
shown to provide only partial protection against Schistosoma
infection with the worm reduction rates being mostly lower than
50% [3]. Therefore, there is an urgent need to develop an
effective vaccine to control and prevent this parasitic disease,
which exerts a heavy personal toll and an economic toll on the
society.
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sive vehicles for delivering antigens to the host. Several oral
vaccines have been developed for clinical use in humans including
vaccines against cholera [9], polio [10] and typhoid [11]. The
carriers used for antigen delivery in these vaccines include
liposomes [12], attenuated Salmonella [13], bacterial spores [14],
and biodegradable microparticles [15]. Salmonella (S.) typhimurium is
a facultative intracellular bacterium and can become colonized in
the cytosol of the host cell such as macrophage. S. typhimurium
induces complex mucosal and systemic immune responses after
oral administration and, because of this property, attenuated S.
typhimurium strains have been used as delivery systems for
heterologous antigen [16]. However, once internalized, S.
typhimurium is confined to membrane-bound vacuoles, which
hinders the presentation of expressed heterologous antigens to
the major histocompatibility complex (MHC). One strategy to
circumvent this restraint is the use of live attenuated S. typhimurium
strains that translocate heterologous antigens into antigen-
presenting cells by means of type III secretion system, a specialized
protein secretion system that delivers a set of bacterial effector
proteins into the host cell cytosol [17,18] or E. coli a-hemolysin
(HlyA) secretion system which is a type I secretion system and fully
active in Salmonella [19,20].
VNP20009 is an attenuated S. typhimurium strain whose safety has
been demonstrated in phase I clinical trial [21]. In the present study,
we used this live attenuated S. typhimurium strain to express chimeric
proteins consisting of the secretion and translocation signals of
Salmonella type III secreted protein Salmonellaouter protein E(SopE) or
a-hemolysin secretion protein (HlyA) fused to S. japonicum antigen
Sj23LHD-GST, the bivalent antigen consisting of the long
hydrophilic domain of Sj23 (Sj23LHD), which contains main T
and B cell epitopes of Sj23 antigen [22], and GST (Sj26) in S.
japonicum. The nitrite reductase B (nirB) and phoP activated gene C
(pagC) promoter from S. typhimurium which are highly active in the
intracellular environment of professional antigen presenting cellssuch
as macrophage [23], were used to drive the expression of Sj23LHD-
GST in S. typhimurium. Here, we sought to study in vitro expression of
Sj23LHD-GST deliveredby theserecombinantS.typhimuriumvaccine
strains and characterize the immune responses elicited by Sj23LHD-
GST in the immunized mice and further investigated the efficacies of
the oral recombinant S. typhimurium vaccines against S. japonicum
infection in a mouse model of schistosomiasis.
Materials and Methods
Plasmids
We cloned the nirB gene promoter (EMBL bank DQ841278.1)
and the phoP-activated C (pagC) gene promoter (EMBL bank
EF191162.1) from E. coli and S. typhimurium genomic DNA
respectively and inserted separately into plasmid pQE30 (Qiagen)
between the restriction site of XhoI and BamHI. The DNA
fragment encoding the N-terminal amino acids 1–104 of sopE
(sopE1–104) (Genebank NC003197), which are recognized as the
secretion signal of SopE [17], was obtained from S. typhimurium
genomic DNA and cloned into the restriction site between BamHI
and KpnI downstream of the nirB gene promoter or pagC
promoter. DNA fragment carrying the Sj23LHD-GST fusion gene
(Genebank M63706, Genebank M14654), which was generated by
overlap PCR, was then cloned into the restriction site between
KpnI and HindIII. The newly constructed plasmids were
designated plasmid nirB-sopE1–104-Sj23LHD-GST and pagC-
sopE1–104-Sj23LHD-GST. Additionally, for construction of
pMohly1-Sj23LHD-GST, Sj23LHD-GST was inserted into the
single NsiI site of the export vector pMohly1, which was kindly
provided by Prof. YX Zhang (East China University of Science
and Technology). The diagrams of plasmid constructs used in the
study are shown in Fig. 1A. The primers used for the above
constructions are indicated in Table S1. Sj23LHD-GST gene was
replaced by EGFP (Enhanced Green Fluorescent Protein) for its
respective EGFP expression plasmid. Lipid A-modified (msbB
2)
auxotrophic (purI
2) S. typhimurium strain VNP 20009 (ATCC,
Manassas, VA, USA) was cultured in LB media. All of the
plasmids and constructions were transformed into S. typhimurium
VNP20009 by electroporation.
Western blotting and in vitro macrophage cell line
RAW264.7 infection assay
Recombinant S. typhimurium was grown at appropriate condi-
tions. Proteins in the culture supernatant were prepared by
precipitation with 10% trichloroacetic acid (v/v) for 1 h on ice.
The bacteria lysates were prepared by sonication. Immunoblotting
was performed using anti-Sj23LHDGST anti-serum as previously
described [24]. Mouse anti-Sj23LHD-GST anti-serum was
produced by immunizing mouse with the recombinant Sj23
LHD-GST protein (rSj23LHD-GST) (produced in E.coli).
For macrophage infection assay, RAW264.7 cells were obtained
from the American Type Culture Collection (ATCC TIB 71) and
maintained in DMEM medium supplemented with 10% fetal
bovine serum by routine culture methods. S. typhimurium harbored
EGFP delivery plasmids were infected with RAW264.7 cells at a
multiplicity of infection (MOI) of 100 after cells for 1 hour, then
washed with phosphate buffered saline (PBS) there times to
remove extracellular bacteria and further cultured with medium
containing 50 mg/ml gentamicin and 10% fetal calf serum for
24 hours before observation under fluorescence microscope.
Immunization of mice
6–8 weeks old female BALB/c mice were purchased from
Shanghai Slac Laboratory Animal Co, Ltd (Shanghai, China) and
maintained in specific pathogen-free, environmentally controlled
conditions (22uC, a 12-h light/dark cycle with the light cycle from
6:00 to 18:00 and the dark cycle from 18:00 to 6:00) according to
standard laboratory chow. Mice were randomly grouped (12 mice
per group) and inoculated by gavage with 0.2 ml PBS containing
10
9 colony forming units (CFUs) of recombinant S. typhimurium or
S. typhimurium carrying pQE30 empty vector three times at an
interval of 2 weeks and control mice received 0.2 ml PBS. For
Author Summary
Schistosomiasis japonica is a zoonotic parasitic disease and
occurs predominantly in Southeast Asia and China. Using a
simple, cheap, yet efficient oral method to deliver the
vaccine antigen would benefit to control its transmission
in that the oral vaccine could be made into a preparation
and mixed with feedstuffs of livestock hosts. In this study,
we used an attenuated S. typhimurium strain VNP20009,
whose safety has been demonstrated in phase I clinical
trial, to express the bivalent Schistosoma japonicum
antigen Sj23LHD-GST by an intracellular activated promot-
er (nirB) and deliver it to host cells through type III
secretion system. After oral vaccination of this recombi-
nant strain, efficient protection against S. japonicum
challenge was induced in mice. Mean while, granuloma
formation in the liver was improved significantly in the
immunized mice. This protective immune response was
Th1 specific type as evidenced by increase in the
production of IL-12 and IFN-c. This work provides an
alternative S. japonicum vaccine for livestock and humans.
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oral immunization with recombinant S. typhimurium, mice were
boosted once by subcutaneous inoculation of 50 mg rSj23LHD-
GST in 0.2 ml PBS. For homologous protein immunization, mice
were inoculated subcutaneously with 50 mg rSj23LHD-GST three
times at an interval of 2 weeks. The animals study protocol was in
according with the guideline of administration of lab animals
issued by the Ministry of Science and Technology (Benjing, China)
and approved by the Jiangsu Institutional Animal Care and Use
Committee (IACUC).
Determination of antigen specific IgG antibody titers
Enzyme linked immunosorbent assay (ELISA) was performed to
detect Sj23LHD-GST specific antibody. Briefly, rSj23LHD-GST
protein was diluted in 50 mM carbonate buffer (pH 9.6) to 10 mg/
ml, and 100 ml was then added to each well on 96-well plates and
were incubated at 4uC overnight for antigen coating. Each plate
was washed three times with PBS (pH 7.6) containing 0.05%
Tween-20 (PBST), and blocked with 3% (w/v) bovine serum
albumin (BSA) in PBS for 3 h at 37uC. The plates were further
washed three times with PBST, and then incubated with the
mouse immune sera serially diluted in PBS for detection of IgG,
IgG1, and IgG2a at 37uC for 1 h. The plates were then washed five
times with PBST, followed by incubation with HRP-conjugated
goat-anti-mouse IgG, IgG1, and IgG2a (Santa Cruz Biotechnology,
Santa Cruz, CA) for 45 min at 37uC. The plates were washed five
times with PBST and were developed with tetramethylbenzidine
substrate and read at 450 nm after the reaction was terminated
using 2 M sulphuric acid.
Determination of plasmid stability in vivo
For determination of plasmid stability in vivo, mice were orally
inoculated with 1610
9 CFUs of non-transformed S. typhimurium or
recombinant S. typhimurium strains. The spleens and Peyer’s
patches were collected and weighed 3, 10 and 20 d after the
inoculation. The tissues were homogenized in PBS at a ratio of 5:1
Figure 1. Secretory expression of recombinant Sj23LHD-GST by S. typhimurium. Diagram of plasmid constructs used in the study (A). nirB,
pagC and pMohly represent nirB-sopE-Sj23LHD-GST, pagC-sopE-Sj23LHD-GST and pMohly1-Sj23LHD-GST constructs, respectively. Plasmids
expressing the recombinant protein of Sj23LHD-GST fused to type III secretion signal of Salmonella outer protein E (SopE) (sopE-Sj23LHD-GST) or
type I secretion signal of a-hemolysin A (HlyA) (hlyA-Sj23LHD-GST) were transformed into Salmonella. Whole bacteria lysates and cultured
supernatants of these strains were examined for the presence of the chimeric protein sopE–Sj23LHD-GST or hlyA-Sj23LHD-GST by Western blotting as
described in Methods (B). Mouse macrophage cell line RAW 264.7 was infected with Salmonella harboring plasmids expressing EGFP as a marker for
the expressed recombinant proteins. The presence and location of EGFP in the cell were examined (C).
doi:10.1371/journal.pntd.0001313.g001
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agar plates with or without antibiotic selection to determine the
counts of recombinant and total bacteria, respectively.
Flow cytometry assay
Mouse spleens were collected at two weeks after last
immunization, then ground and sieved to obtain single cell
suspension. After lysis of red blood cells, 2610
6 cells per well were
planted in 24-well plates and cultured in RPMI 1640 containing
10% FBS. After stimulation with 20 mg/ml rSj23LHD-GST for
16 h, the cells were stained for cell surface markers using anti-
CD4-PEcy5 (Phycoerythrin-Cy5), CD8-PEcy5 and CD69-FITC
(fluoresceinisothiocyanate) antibodies (BD Biosciences, USA) in
the dark for 45 min. After washing in PBS, the cells were
resuspended and then analyzed by flow cytometry. For detection
of CD44 expression, splenocytes were collected at two weeks after
the last immunization and then directly stained with anti-CD44-
PE (Phycoerythrin) antibodies (BD Biosciences, USA) and
analyzed.
Measurement of cytokines
For determination of IFN-c and IL-4 concentrations, two mice
were randomly selected from each group and sacrificed two weeks
after the 3
rd immunization. Single-cell suspensions were prepared
by pooling splenocytes of the two mice from each group. Red
blood cells were lysed and the cells were cultured in RPMI 1640
media supplemented with 10% fetal bovine serum (FBS). A total of
6610
5 cells per well were cultured in triplicate wells for each group
for 72 h at 37uC with 5% CO2 in 96-well plates in the presence of
10 mg/ml recombinant Sj23LHD protein(rSj23LHD) (produced
in E.coli), 10 mg/ml recombinant GST protein(rGST)( produced in
E.coli), 10 mg/ml ConA or media alone. IFN-c and IL-4 levels in
the supernatant were determined using commercially available
ELISA kits (ExCell, Shanghai, China). For multiple cytokines
assay using the Bio-Plex system, splenocytes from mice in each
group were stimulated with rGST (10 mg/ml) for 48 h and the
culture supernatants were assayed according to the manufacturer’s
instruction (Bio-Rad Laboratories, California, USA).
S. japonicum cercariae skin penetration assays
Snails infected with S. japonicum were obtained from Jiangsu
Institute of Parasitic Diseases and cercariae of S. japonicum were
collected from the infected snails. Two weeks after the last
immunization, every mouse in each group (12 mice per group) was
challenged with 4061 S. japonicum cercariae by abdominal skin
penetration. Forty-two days post-challenge, all mice were
sacrificed to determine worm and liver egg burdens. Adult worms
were recovered by portal vein perfusion and calculated, part of the
liver was cut, weighed, and digested with 5 ml 5% KOH at 37uC
overnight, then dropped 50 ml liver homogenate on the glass
counting slide to determine the egg number under microscope.
The worm reduction rate was determined using the formula: (the
average worm burden in the control group-the average worm
burden in the experimental group)/the average worm burden in
control group6100%. The egg reduction rate was determined
using the formula: (the number of eggs per gram in the control
group–the number of eggs per gram in the experimental group)/
the number of eggs per gram in the control group6100%. In
addition, part of the liver (1–5 cm
3) from challenged mice was cut
and fixed in 4% neutralized formaldehyde. After the tissues were
embedded in paraffin, they were sectioned for hematoxylin-eosin
(H&E) staining according to standard histological procedures.
Granuloma formation in the livers was observed under a light
microscope and at least 15 granulomas per tissue section were
analyzed for granuloma area using a computerized image analysis
system (Smartscape 2002, China).
Statistics
Quantitative data were expressed as mean 6 standard deviation
(SD) and analyzed using the SPSS software. Paired Student’s t test
was performed to assess statistical significance. Differences
between experimental groups were considered significant if the P
value was less than 0.05.
Results
Recombinant S. typhimurium strains effectively express
and deliver the antigen to the cytosol of macrophage by
type III secretion system in vitro
For rational design of an effective vaccine strain, we constructed
plasmid vectors expressing chimeric proteins of sopE1–104,N -
terminal 1–104 amino acids of sopE which are recognized as the
secretion signal for type III secretion system, fused to S. japonicum
antigen Sj23LHD-GST driven by the nirB or pagC promoter
(Fig. 1A). nirB is activated by anaerobic conditions and pagC is
inhibited by high magnesium concentration, these two promoters
are both highly active in intracellular environment of professional
antigen presenting cells [23]. Additionally, we constructed the
other plasmid called pMohly1-Sj23LHD-GST, which delivering
the antigen through a-hemolysin (HlyA) secretion system and
driven by original hlyA promoter. pMohly1 is a plasmid comprises
all the components of E. coli a-hemolysin secretion system included
hlyB, hlyC, hlyD and secretion signal of target molecule hlyA [19].
We transformed the S. typhimurium strain VNP20009 with the
appropriate plasmid vectors and examined the efficiency of the
production of the recombinant proteins by immunoblotting using
anti-Sj23LHD-GST anti-serum. We found that both recombinant
proteins sopE-Sj23LHD-GST and hlyA-Sj23LHD-GST driven by
the respective promoter were effectively produced by S. typhimurium
(Fig. 1B) Additionally, immunoblotting analysis of the culture
supernatant revealed the presence of the chimeric protein sopE–
Sj23LHDGST or hlyA-Sj23LHDGST, suggesting the efficient
secretion of these chimeric proteins from the transformed bacteria.
We next examined whether the recombinant chimeric proteins
were delivered to the cytosol of macrophages after infection by S.
typhimurium harboring the appropriate plasmid vectors. We infected
mouse macrophage cell line RAW 264.7 with pagC-sopE-EGFP,
nirB-sopE-EGFP or pMohly1-EGFP. Florescent microscopy indi-
cated thatthe recombinantproteinswereeffectivelyexpressedinthe
infected macrophages by S. typhimurium carrying all three expression
vectors (Fig. 1C). In addition, noticeably higher fluorescence inten-
sity was detected by S. typhimurium carrying pagC-sopE-EGFP than
the other two strains which indicated that this recombinant strain
expressed higher protein level. These results indicate that
recombinant S. typhimurium strains can effectively and efficiently
express Sj23LHD-GST and deliver the recombinant protein to the
cytosol of macrophages in vitro by type III secretion system.
Sj23LHD-GST delivered by S. typhimurium driven by the
nirB promoter elicits a Th1 specific humoral response in
mice
We further examined whether Sj23LHD-GST delivered by S.
typhimurium could elicit effective humoral immune response in mice
orally immunized with recombinant S. typhimurium strains. ELISA
results showed that delivered antigen elicited the highest titer of
serum IgG against Sj23LHD-GST in mice immunized with S.
typhimurium harboring pagC-sopE-Sj23LHD-GST while no signif-
Oral Vaccine Development for S. japonicum
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typhimurium harboring pMohly1-Sj23LHD-GST. In addition,
Sj23LHD-GST only elicited a very moderate level of IgG in mice
immunized with S. typhimurium harboring nirB-sopE-Sj23LHD-
GST (Fig. 2A). Differently from total IgG level, the IgG2a:IgG1
ratio (IgG2a/IgG1) in mice immunized with S. typhimurium
harboring nirB-sopE-sj23LHD-GST was the highest (Fig. 2B).
The wide dominance of IgG2a isotype strongly suggests that nirB-
sopE-Sj23LHD-GST strain triggered a specific Th1-type response
in mice.
The plasmid vectors expressing Sj23LHD-GST driven by
the nirB promoter in S. typhimurium were stable in the
inoculated mice
Due to the fact that there was no selection pressure in the mice
body, we sought to investigate whether the plasmid vectors
expressing the appropriate antigens were stably present in the
immunized mice by determining the colonization of recombinant S.
typhimurium strains in murine tissues. No significant difference was
found in the number of recombinant bacteria recovered from the
spleens and Peyer’s patches of mice inoculated with S. typhimurium
strains harboring nirB-sopE-Sj23LHD-GST or pMohly1-
Sj23LHD-GST compared with that of mice inoculated with wild
type S. typhimurium while the number of recombinant bacteria
recovered from the spleen of mice immunized with S. typhimurium
strain harboring pagC-sopE-Sj23LHD-GST was markedly lower
(Fig. 3).Furthermore, no S. typhimurium strainharboring pagC-sopE-
Sj23LHD-GST was recovered from Peyer’s patches at 3 d post
inoculation (Fig. 3). The findings suggested that plasmids expressing
nirB-sopE-Sj23LHD-GSTwerestablewhilethoseexpressingpagC-
sopE-Sj23LHD-GST were not stable in mice.
Sj23LHD-GST delivered by S. typhimurium driven by the
nirB promoter induces activation of T cells in immunized
mice
CD44 is a leukocyte homing associated adhesion molecule and
a marker of activation and memory T cells [25]. We examined
CD44 expression on splenocytes of mice immunized with the
appropriate recombinant S. typhimurium strains by flow cytometry.
We found a distinctly increased subpopulation of CD44
+ cells in
the splenocytes (2562%) from mice immunized with Sj23LHD-
GST delivered by S. typhimurium type III secretion system driven by
the nirB promoter, which was significantly higher than that found
in mice immunized with S. typhimurium strains harboring pagC-
sopE-Sj23LHD-GST (1261%) or pMohly1-Sj23LHD-GST
(1161%) or vector (1161%) (P,0.01) (Fig. 4A, 4D). We further
Figure 2. Humoral response elicited by vaccination with recombinant Salmonella strains. BALB/c mice were orally immunized with nirB
strain, pagC strain, pMohly strain, vector strain or PBS (control) 3 times at 2 weeks interval. Two weeks after the last immunization, serum samples
were collected and assayed by ELLISA. The recombinant Sj23LHDGST protein was used as the coating antigen. (A) The total antigen-specific IgG
production in serial dilutions (1:50, 1:100, 1:200, and 1:400). Each bar and symbol represents the mean 6 SD of sera from 8 mice. (B) The ratio of IgG2a
to IgG1 in mouse serum (diluted 1:50) from each group was calculated. The column represents the mean absorbance of IgG2a divided by the mean
IgG1 absorbance of 8 animals. *P,0.05 and **P,0.01.
doi:10.1371/journal.pntd.0001313.g002
Figure 3. Colonization of the spleens (A) and Peyer’s patches (B) of BALB/c mice following oral inoculation with recombinant S.
typhimurium vaccines and wild type S. typhimurium carrying no plasmid (Sal) (white bar). The organs were collected from 3 animals 3, 10 or
20 d after inoculation and homogenized in PBS and plated onto agar for bacteria counting. Data are presented as mean 6 SD, n=3; N.D. represents
no detection. **P,0.01 and ***P,0.001 when compared with non-transformed S. typhimurium (Sal).
doi:10.1371/journal.pntd.0001313.g003
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antigen-specific stimulation of mature T cells [26], in CD4
+ or
CD8
+ splenetic T cells following antigen stimulation from mice
immunized with the appropriate recombinant S. typhimurium strains
by flow cytometry. We observed that Sj23LHD-GST delivered by
S. typhimurium type III secretion system driven by the nirB
promoter caused a significant increase in the percentage of
CD69
+CD4
+ (1.460.1%) and CD69
+CD8
+ (1.260.2%) cells
compared with those of vector (0.960.1% for CD69
+CD4
+ cells
and 0.560.1% for CD69
+CD8
+ cells) (P,0.05) (Fig. 4B–4C, 4E–





cells was higher in mice immunized with pagC-sopE-Sj23LHD-
GST or pMohly1-Sj23LHD-GST, it was not statistically signifi-
cantly different from that of vector.
Sj23LHD-GST delivered by S. typhimurium driven by the
nirB promoter protects against infection of mice by S.
japonicum
To investigate whether our oral recombinant S. typhimurium
vaccine strains were effective against S. japonicum infection, we
Figure 4. Expression of CD44 and activation of CD69. BALB/c mice were orally immunized 3 times, 2 weeks interval, with nirB strain, pagC
strain, pMohly strain, vector strain or PBS (control). Splenocytes collected 2 weeks after the 3
rd immunization were stained with CD44-PE and assayed
by flow cytometry. Histograms (A) and quantitation (D) are shown. For CD69 activation of CD4 and CD8 T cells in the presence of recombinant
heterologous antigens, splenocytes collected 2 weeks after the 3
rd immunization were stimulated by the sj23LHDGST protein for 16 h and then
doubly stained with CD4-PEcy5 and CD69-FITC or CD8-PEcy5 and CD69-FITC. Dot plots assayed by flow cytometry (B, C) and the percentage of
CD8+CD69+ double positive cells (E) and CD4+CD69+ double positive cells (F) are showed. Each column represents the mean 6 SD of 3 independent
experiments in duplicate. *P,0.05 and ***P,0.001.
doi:10.1371/journal.pntd.0001313.g004
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by abdominal skin penetration. Six weeks after the challenge, we
examined the worm and egg burden in the vena mesenteria and
liver of mice. The recombinant S. typhimurium strains harboring
pagC-sopE-Sj23LHD-GST, nirB-sopE-Sj23LHD-GST or pMoh
ly1-Sj23LHD-GST caused a 26.89%, 41.69% or 32.93% redu-
ction, respectively, in the number of adult worms and 30.07%,
57.71% and 40.46% reduction, respectively, in the number of eggs
(Table 1). Consistent with its induction of high IgG2a/IgG1 ratios,
Sj23LHD-GST driven by the nirB promoter was most effective in
suppressing the worm burn in the immunized mice challenged
with S. japonicum cercariae, demonstrating the in vivo protection
efficacy results from antigens delivered by S. typhimurium type III
secretion system driven by the potent anaerobia-inducible nirB
promoter.
Immunization with S. typhimurium-nirB-sopE-Sj23LHD-
GST induce a predominant Th1-specific cytokine
response
To characterize the cytokine response induced by recombinant
S. typhimurium vaccine strains, we measured the production of IFN-
c and IL-4 by splenocytes of immunized mice. We isolated and
stimulated the splenocytes with recombinant Sj23LHD or GST
and determined the cytokines levels by ELISA. As shown in Fig. 5,
splenocytes of mice immunized with S. typhimurium harboring nirB-
sopE-Sj23LHD-GST generated noticeably higher IFN-c levels
than splenocytes of mice immunized with the other recombinant S.
typhimurium strains. Besides, the IL-4 production was too low to
determine in the splenocyte supernatant after antigen stimulation
for 72 hour (data not shown).
Many studies suggested that heterologous prime–boost vacci-
nation by different types of vaccines containing the same antigen
could be more immunogenic than traditional homologous
vaccination [27]. To obtain stronger immune response to
Sj23LHD-GST antigen delivered by recombinant nirB strain,
we immunized mice with recombinant S. typhimurium harboring
nirB-sopE-sj23LHD-GST followed by booster immunization with
the Sj23LHD-GST protein once and examined the production of
multiple cytokines by splenocytes of immunized mice by high
throughput analysis. Consistent with the results of ELISA assay,
we found that the splenocytes of mice immunized with S.
typhimurium-nirB-sopE-Sj23LHD-GST or S. typhimurium-nirB-
sopE-Sj23LHD-GST followed by booster immunization produced
noticeably higher levels of Th1-specific cytokines (IL-2, IL-12 and
IFN-c) compared with those of mice immunized with the
Sj23LHD-GST protein or vector (Table 2). Besides, splenocytes
from mice immunized with nirB prime-protein boost regime
Table 1. S. japonicum burden in mice immunized with








Control 11 3063 122699634214
Vector 12 2663 (14.98) 100398621669
(18.17)
nirB-sopE-Sj23LHD-GST 11 1763 (41.69***) 51889612888
(57.71***)
pagC-sopE-Sj23LHD-GST 12 2262 (26.89*) 85805625299
(30.07*)
pMohly1-Sj23LHD-GST 11 2063 (32.93**) 73058625481
(40.46**)
Data are presented as mean 6 SD, n=11–12;
*P,0.05,
**P,0.01,
***P,0.001 compared with vector.
doi:10.1371/journal.pntd.0001313.t001
Figure 5. IFN-c production by splenocytes of immunized mice. BALB/c mice were orally immunized 3 times, 2 weeks interval, with nirB strain,
pagC strain, pMohly strain, vector strain or PBS (control). The splenocytes of immunized mice were collected at 2 weeks after the 3
rd immunization
and stimulated with recombinant Sj23LHD protein (10 mg/ml), GST protein (10 mg/ml), conA (10 mg/ml) or media alone. The content of IFN-c in the
culture supernatant was measured by ELISA kit. Each column represents the mean6SD of 3 independent experiments. ***P,0.001 when compared
with vector group.
doi:10.1371/journal.pntd.0001313.g005
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with nirB strain alone (103.7613.3 pg/ml) (Table 2).
Heterologous prime–boost vaccination is more effective
in protecting against infection of mice by S. japonicum
Then, we examined the protective efficacy of nirB prime-
protein boost vaccination. Analysis of the worm burden in the
immunized mice showed that immunization with the Sj23LHD-
GST protein and Sj23LHD-GST delivered by S. typhimurium type
III secretion system driven by the nirB promoter caused a 21.62%
and 42.73% reduction in the worm burden, respectively (Table 3)
while the greatest reduction in worm burden (51.35%) was
observed in mice immunized by the prime-boost method.
Furthermore, the prime boost vaccination caused a 62.59%
reduction in the S. japonicum egg burden, which was significantly
higher than that by the recombinant protein alone or Sj23LHD-
GST delivered by nirB driven S. typhimurium type III secretion
system. We additionally examined granuloma formation in the
liver of mice immunized with the Sj23LHD-GST protein, the
recombinant S. typhimurium nirB strain and the heterologous prime-
boost vaccination by microscopic examination of H&E-stained
sections. The area of granuloma in the liver of mice immunized
with nirB strain and nirB prime-boost vaccination were signifi-
cantly smaller compared with those immunized with the
Sj23LHD-GST protein or vector (Fig. 6). Besides, the granulomas
in the liver of mice in the nirB prime-boost vaccination were the
smallest (Fig. 6).
Discussion
Schistosomiasis japonica is a zoonotic parasitic disease and infection
occurs following direct contact with the larval forms of the parasite
known as cercariae, which could infect humans and other
mammalian hosts including buffaloes, pigs, sheep, and dogs. The
eggs in feces released from the livestock hosts provide the main
mode of transmission and veterinaryuse should be firstly considered
for schistosome vaccine design [3]. For veterinary vaccine
development, oral inoculation is convenient as it could be made
into a preparation and mixed with feedstuffs. Additionally,
schistosome infection occurs predominantly in areas of rural
poverty in sub-Saharan Africa, Southeast Asia and tropical regions
of the Americas [28]. Attenuated Salmonella expressing and
delivering heterologous antigen could offer an economical vehicle
forvaccine development, whichmaygreatlybenefitunderprivileged
populations around the world and the production costs of bacterial
culture, operation and transport are far lower than those of
Table 2. The cytokines produced by splenocytes of mice vaccinated with heterologous prime–boost regime.
Cytokines





IL-1b 175.7656.9 277.7634.7 210.262.6 220.2635.7 235.2645.1 161.7634.1
IL-2 44.366.7 72.965.3 89.9611.1 103.7613.3* 121.466.2*
,# 84.2629.7
IL-3 4.160.5 14.162.8 6.961.3 10.162.3 14.464.6 7.563.1
IL-4 3.963.9 6.966.9 6.166.1 4.564.5 2.162.1 4.564.5
IL-5 2.260.2 2.960.9 5.161.4 2.061.1 1.160.1 1.660.5
IL-6 78.4612.6 396.9628.6 189.9618.3 324.3627.6 372.5662.6 358.4638.1
IL-9 55.764.1 65.264.3 61.067.8 62.8610.1 45.0612.6 46.165.5
IL-10 44.9614.2 74.7623.2 39.765.2 79.469.1 56.766.1 44.669.6
IL-12(p40) 39.462.6 51.566.5 34.965.4 74.668.3* 64.969.0* 57.864.6
IL-12(p70) 59.3612.3 59.764.6 56.766.7 65.4610.0* 72.764.8* 50.867.0
IL-13 114.9628.6 146.9617.2 129.8612.4 129.5617.1 125.2610.6 93.064.5
IL-17 5.161.1 171.2688.4 49.6631.9 66.1625.1 137.8644.5 141.5614.4
Eotaxin 442.6614.0 521.4632.5 487.2668.2 493.2671.2 157.6615.7 369.7653.0
RANTES 542.7674.1 1488.56218.2 670.2626.4 1954.7686.9 1364.76115.9 1360.36119.5
IFN-c 22.266.3 58.2611.8 36.7610.2 165.0681.6** 196.46159.8** 24.469.0
Data are presented as mean 6 SD, n=3;
*P,0.05 and
**P,0.01 compared with vector;
#P,0.05 compared with nirB group.
doi:10.1371/journal.pntd.0001313.t002









Control 12 3162 122533622535
Vector 11 2863 (10.37) 10079769131
(17.74)
Protein 12 2463 (21.62*) 83402611364
(31.93*)
nirB 10 1964 (42.73***) 62205614557
(53.23***)




Vector prime-boost 9 2663 (14.59) 92878623881
(24.20)
Data are presented as mean 6 SD, n=9–12;
*P,0.05 and
***P,0.001 compared with vector;
#P,0.05 compared with nirB group.
doi:10.1371/journal.pntd.0001313.t003
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The safety of VNP20009, an attenuated S. typhimurium strain used in
the current study as a S. japonicum antigen secretory expression
vector, has been confirmed in clinical cancer patients [21]. Our
previous study also showed that oral administration of 10
9 CFUs of
VNP20009 causednoapparenttoxicityinmice[29].Theseindicate
that the attenuated S. typhimurium strain VNP20009 could be a safe
and feasible vehicle for delivery of heterologous antigens.
Attenuated Salmonella has been used to express and translocate
heterologous antigens into antigen-presenting cells by means of
bacteria secretion apparatus [18,19]. For rational design of
recombinant vaccine strains, efficiency of expression and delivery
of heterologous antigens are important determinants of vaccine
efficacy. The efficacy of S. typhimurium as an antigen delivery
vehicle has been hampered by its confinement to membrane-
bound vacuoles after internalization, which hinders the presenta-
tion of expressed heterologous antigens to the MHC molecules.
We took advantage of S. typhimurium type III secretion system by
fusing the target antigen to the secretion and translocation signals
of Salmonella type III secreted protein SopE. Our fluorescent
microscopy demonstrated that the bivalent Sj23LHD-GST
antigen was effectively delivered to the cytosol of infected
macrophages in vitro, implying that Salmonella type III secretion
system could selectively deliver antigen to desirable subcellular
compartments of the target cell, rendering possible effective
antigen presentation by the MHC molecules.
One further restraint of vaccine efficacy using recombinant S.
typhimurium strains is the potential lack of stability of the plasmid
Figure 6. Granulomas formation in the liver. 6 weeks after S. japonicum challenge, the livers of mice immunized with PBS (control), vector,
rSj23LHD-GST, nirB strain, nirB prime-boost or vector prime-boost were collected, fixed and sectioned for hematoxylin-eosin (H&E) staining. (A)
Representative granuloma was shown (magnification,6400) and (B) granuloma area was measured, Mean 6 SD, n=12–15. *P,0.05, and ***P,0.001.
doi:10.1371/journal.pntd.0001313.g006
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Th1-specific immune response and more potent activation of T
cells elicited by Sj23LHD-GST driven by the nirB promoter.
Although we observed higher levels of Sj23LHDGST production
driven by the pagC promoter, only a less vigorous immune
response was elicited by the construct pagC-sopE1–104-Sj23LHD-
GST, indicating that, consistent with the most recent study [30],
high-level expression of heterologous antigens does not necessarily
result in optimal stimulation of immune responses and potent
protection against pathogen challenge. Examination of plasmid
stability in the host revealed that pagC-sopE1–104-Sj23LHD-GST
was unstable in the internal environment of the host with an early
loss of the plasmid vector at 3 days post inoculation. Therefore,
sustained and stable expression of antigens by plasmid vectors is
required to trigger vigorous immune response.
Though several schistosome vaccines have been developed,
these vaccines so far have been shown to provide only partial
protection against Schistosoma infection with the worm reduction
rates being mostly lower than 50% [3]. Some studies have shown
that ultraviolet (UV)-attenuated cercariae of S. japonicum produced
high level protection in artiodactyls, 92% in pigs and 89.1% in
cattle against S. japonicum infections [31,32]. However, investiga-
tors from different laboratories have found that protection in mice
induced by UV-attenuated cercariae is unstable and relatively low
(25%) [33]. One recent study demonstrated that UV-attenuated
cercariae of S. japonicum could not effectively induce a Th1 type
immune response in C57BL/6 mice [34]. A main obstacle in
development of a successful schistosomiasis vaccine is a lack of
consensus on what type of immune response should be induced
[35]. Anyway, the vaccine antigens that specifically induced Th1
immune response have been described to induce promising
protection against infection in the mouse model [7,36,37,38]. In
our study, delivery of Sj23LHD-GST through the anaerobia-
inducible nirB promoter in combination with Salmonella type III
secretion system efficiently elicited remarkable activation of
antigen specific CD4
+ and CD8
+ T cells and high levels IL-2,
IL-12 and IFN-c. Besides, the reduction of eotaxin was observed
in mice immunized by the prime-boost vaccination and this may
result from the high IFN-c level, since IFN-c has been reported to
potently inhibit eotaxin expression [39]. This Th1 predominant
immune response may underlie the in vivo efficacy of the
recombinant vaccine in markedly reducing worm burden and
suppressing granuloma formation in the liver of immunized mice
challenged with cercariae of S. japonicum. We observed here a
41.69% reduction in worm burden in the mice immunized with S.
typhimurium harboring nirB-sopE-Sj23LHD-GST. Further reduc-
tion in the worm burden was realized when mice were immunized
by the heterologous prime–boost strategy with the worm burden
reduced by over 50%, suggesting that the oral recombinant
vaccine could be further explored for development as a possible
venue for preventing Schistosomiasis.
Heterologous prime-boost vaccination strategies, which can be
given with unmatched vaccine delivery system while using the
same antigen, have been successfully applied to many different
types of diseases, including acquired immune deficiency syndrome
(AIDS) [40], tuberculosis [41] and malaria [42] and have shown
greater efficacy than the homologous prime-boost approach when
using the same vaccine delivery system with multi-immunization.
The mechanism of the strategy has not been fully elucidated and
the activation of a broad spectrum of immune responses may
contribute to the enhanced efficacy. DNA vaccines are usually
used for priming propose and recombinant protein vaccines or
viral vaccines are applied for boosting regimes [27]. Oral vaccine
used as a priming regime was rarely reported and this present
study showed that heterologous prime-boost strategies using oral
vaccine priming followed by boosting with recombinant protein
could produce enhanced protective efficacy against S. japonicum
infection
In summary, oral administration of recombinant Salmonella
endowed with the capability of expressing and secreting S.
japonicum antigen induced high protection efficacy in a mouse
model of schistosome infection. Mice immunization with the
recombinant Salmonella strain with the expression of the target
antigen driven by the potent anaerobia-inducible nirB promoter
and secretion of the target antigen to the cytosol of host cells
through Salmonella type III secretion system induced vigorous Th1-
specific immune responses and offered potent protection against
challenge by S. japonicum in mice. Our findings suggest that this
novel vaccine design may provide a safe, cheap, efficient and
convenient approach for schistosome vaccine development.
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